Psychotropic Medication Classes for Bipolar Disorder
The primary psychotropic medication classes used to treat bipolar disorder are mood stabilizers (lithium and anticonvulsants) and atypical antipsychotics, with antidepressants used only as adjunctive therapy—never as monotherapy. 1, 2
Core Medication Classes
First-Line Agents
Mood Stabilizers:
- Lithium - The gold standard with unique antisuicide effects and FDA approval down to age 12 for acute mania and maintenance 1, 2
- Anticonvulsants - Valproate (divalproex), lamotrigine, and carbamazepine 1, 3
Atypical Antipsychotics:
- Quetiapine, aripiprazole, olanzapine, risperidone, asenapine, lurasidone, cariprazine, and ziprasidone 1, 2
- These agents are FDA-approved for acute mania in adults and increasingly used as primary treatment 1
Phase-Specific Treatment Approach
For Acute Mania: Standard therapy includes lithium, valproate, and/or atypical antipsychotics 1. The term "mood stabilizer" is somewhat misleading—most agents have clearly demonstrated efficacy primarily for acute manic symptoms, making "antimanic" a more accurate descriptor 1.
For Bipolar Depression:
- Quetiapine (particularly effective in monotherapy or adjunctive treatment) 3, 4
- Lurasidone 2, 4
- Olanzapine + fluoxetine combination 1, 3
- Lamotrigine 1, 4
Treatment of bipolar depression remains the most challenging phase, with considerably fewer effective options than for mania 1, 3.
For Maintenance/Prophylaxis:
- Lithium and lamotrigine are FDA-approved for maintenance therapy 1
- Olanzapine also has maintenance approval 1
- Valproate used off-label 3
- Growing use of modern antipsychotics for long-term prophylaxis 3
Adjunctive Medication Classes
Benzodiazepines: Used to stabilize acute agitation and sleep disturbance in mania, though they may cause disinhibition in younger children 1
Antidepressants (SSRIs or non-tricyclics): May be useful adjuncts for depression only when the patient is also taking at least one mood stabilizer 1. Critical caveat: antidepressants are not recommended as monotherapy 2 because they may destabilize mood or precipitate manic episodes 1. Antidepressants increase intracellular sodium, which may explain why they destabilize the illness 5.
Important Clinical Considerations
Polypharmacy is Common: The most frequently used combination is mood stabilizer plus antipsychotic co-treatment (36-44% of patients) 6. While monotherapy is theoretically preferred, combination treatment is standard in clinical practice 7. However, care should be taken to avoid unnecessary polypharmacy 1.
No Single Agent Treats All Phases: No medication is FDA-approved for all phases of bipolar disorder (acute mania, acute depression, and maintenance treatment) 1. This necessitates phase-specific treatment strategies.
Medication Selection Factors: Choice should be based on: (1) evidence of efficacy, (2) phase of illness, (3) confounding presentations (rapid cycling, psychotic symptoms), (4) side effect profile and safety, (5) patient's medication history, and (6) patient/family preferences 1.
Common Pitfall - Antidepressant Monotherapy: A manic episode precipitated by an antidepressant is characterized as substance-induced per DSM criteria 1. Manic symptoms with SSRIs may represent unmasking of bipolar disorder or disinhibition from the agent 1.
Weight Gain Concern: Atypical antipsychotics carry significant risk of weight gain, particularly problematic in youth populations 1. This contributes to the 37% prevalence of metabolic syndrome in bipolar patients 2.
Mechanism-Based Rationale
The most reproduced biologic abnormality in bipolar disorder is elevated intracellular sodium during illness phases 5. Lithium and mood stabilizers directly reduce or normalize intracellular sodium concentrations in an activity-dependent fashion, making them preferred first-line agents 5. Antipsychotics indirectly lower intracellular sodium through D2 receptor blockade, supporting their role as reasonable adjunctive or second-line agents 5.